| 000 | 01087cam a2200169 4500500 | ||
|---|---|---|---|
| 005 | 20260322001915.0 | ||
| 041 | _afre | ||
| 042 | _adc | ||
| 100 | 1 | 0 |
_aRoblin, Xavier _eauthor |
| 700 | 1 | 0 |
_aBarrau, Mathilde _eauthor |
| 245 | 0 | 0 | _aToward personalized medicine with anti-TNF? Not yet . . . |
| 260 | _c2024. | ||
| 500 | _a36 | ||
| 520 | _aThere is a link between the presence of the HLA DQA1-05 allele and the development of anti-TNF antibodies. Testing for the HLA DQA1-05 variant makes it possible to isolate patients with a high immunogenic risk under anti-TNF therapy, but its sensitivity and specificity are insufficient to propose precise algorithms based on the results. This test, therefore, remains a decision-support tool. Elevated IFX clearance identifies the patients at greatest risk of requiring a colectomy to treat severe acute colitis. | ||
| 786 | 0 | _nHépato-Gastro & Oncologie Digestive | 31 | 1 | 2024-01-01 | p. 29-32 | 2115-3310 | |
| 856 | 4 | 1 | _uhttps://stm.cairn.info/journal-hepato-gastro-oncologie-digestive-2024-1-page-29?lang=en&redirect-ssocas=7080 |
| 999 |
_c1718854 _d1718854 |
||